TY - JOUR
T1 - Preparation and anticoagulant activity of fully O-sulphonated glycosaminoglycans
AU - Toida, Toshihiko
AU - Maruyama, Tomohiro
AU - Ogita, Yoshiaki
AU - Suzuki, Atsushi
AU - Toyoda, Hidenao
AU - Imanari, Toshio
AU - Linhardt, Robert J.
N1 - Funding Information:
We thank Shin Nippon Yakugyo Co., Ltd. (Tokyo, Japan) and New Zealand Pharmaceuticals Ltd. (Palmerston North, New Zealand) for supplying GAGs. This work was supported in part by Grants-in-Aid from the Ministry of Culture and Education of Japan (09672185 (TT) and 09470490 (TI)), Nakatomi Foundation (TT) and the NIH (GM 38060 and HL 52622 (RJL)).
PY - 1999/12/1
Y1 - 1999/12/1
N2 - Glycosaminoglycans including dermatan sulphate, hyaluronan, heparan sulphate and heparin were chemically modified by O-sulphonation. By altering the reaction conditions, products having a different degree of O-sulphonation could be obtained. Glycosaminoglycan derivatives were prepared having no free hydroxyl groups, with sulphoester group/disaccharide unit ratios of 4.0 for dermatan sulphate and hyaluronan, and sulphoester and sulphamide group/disaccharide unit ratios of 4.22 and 4.88 for heparan sulphate and heparin, respectively. 1H NMR spectroscopy showed that the fully O-sulphonated hyaluronan derivative had a glucuronate residue with an altered conformation. Since glycosaminiglycans and their derivatives are often used as anticoagulant/antithrombotic agents, their anti-amidolytic activities were determined. The anti-factor IIa activity of fully O-sulphonated dermatan sulphate, hyaluronan and heparan sulphate ranged from 40 to 80 units/mg, while no anti-factor Xa activity of the fully O-sulphonated glycosaminoglycans was detected. These values are lower than those reported for low-molecular-weight heparins and are consistent with the requirement of an antithrombin III pentasaccharide binding site for anti-factor Xa activity. Interestingly, the anti-factor Xa of heparin is lost by chemical O-sulphonation. Copyright (C) 1999 Elsevier Science B.V.
AB - Glycosaminoglycans including dermatan sulphate, hyaluronan, heparan sulphate and heparin were chemically modified by O-sulphonation. By altering the reaction conditions, products having a different degree of O-sulphonation could be obtained. Glycosaminoglycan derivatives were prepared having no free hydroxyl groups, with sulphoester group/disaccharide unit ratios of 4.0 for dermatan sulphate and hyaluronan, and sulphoester and sulphamide group/disaccharide unit ratios of 4.22 and 4.88 for heparan sulphate and heparin, respectively. 1H NMR spectroscopy showed that the fully O-sulphonated hyaluronan derivative had a glucuronate residue with an altered conformation. Since glycosaminiglycans and their derivatives are often used as anticoagulant/antithrombotic agents, their anti-amidolytic activities were determined. The anti-factor IIa activity of fully O-sulphonated dermatan sulphate, hyaluronan and heparan sulphate ranged from 40 to 80 units/mg, while no anti-factor Xa activity of the fully O-sulphonated glycosaminoglycans was detected. These values are lower than those reported for low-molecular-weight heparins and are consistent with the requirement of an antithrombin III pentasaccharide binding site for anti-factor Xa activity. Interestingly, the anti-factor Xa of heparin is lost by chemical O-sulphonation. Copyright (C) 1999 Elsevier Science B.V.
KW - Anticoagulant activity
KW - Chemical oversulphonation
KW - Glycosaminoglycan
UR - http://www.scopus.com/inward/record.url?scp=0032725959&partnerID=8YFLogxK
U2 - 10.1016/S0141-8130(99)00088-4
DO - 10.1016/S0141-8130(99)00088-4
M3 - Article
C2 - 10569284
AN - SCOPUS:0032725959
SN - 0141-8130
VL - 26
SP - 233
EP - 241
JO - International Journal of Biological Macromolecules
JF - International Journal of Biological Macromolecules
IS - 4
ER -